HUTCHMED (China) Limited Cash Flow Conversion Efficiency
HUTCHMED (China) Limited cash flow conversion efficiency. Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) has a cash flow conversion efficiency ratio of -0.140x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-89.37 Million ≈ $-104.48 Million USD) by net assets (€636.87 Million ≈ $744.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of HUTCHMED (China) Limited for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of HUTCHMED (China) Limited (2016–2025)
Cash flow conversion efficiency of HUTCHMED (China) Limited from 2016 to 2025. This chart illustrates how HUTCHMED (China) Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HUTCHMED (China) Limited stock price for real-time trading data and today's change.
HUTCHMED (China) Limited Cash Flow Conversion Ratio Explained
HUTCHMED (China) Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
HUTCHMED (China) Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HUTCHMED (China) Limited ranked by their cash flow conversion efficiency. Review H7T1 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Extendicare Inc
TO:EXE
|
0.146x |
|
Formula Systems (1985) Ltd
F:FSY
|
N/A |
|
Fraser Neave Holdings Bhd
KLSE:3689
|
0.027x |
|
Kinnevik Investment AB ser. B
ST:KINV-B
|
-0.002x |
|
Evertec Inc
NYSE:EVTC
|
0.126x |
|
Xiamen Port Development Co Ltd
SHE:000905
|
0.062x |
|
Butterfly Network Inc
NYSE:BFLY
|
-0.086x |
|
Huaxia Eye Hospital Group Co. Ltd. A
SHE:301267
|
N/A |
Annual Cash Flow Conversion Efficiency for HUTCHMED (China) Limited (2016–2025)
The table below shows the annual cash flow conversion efficiency of HUTCHMED (China) Limited from 2016 to 2025. Also see HUTCHMED (China) Limited balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.25 Billion ≈ $1.46 Billion |
€-64.66 Million ≈ $-75.59 Million |
-0.052x | -8125.01% |
| 2024-12-31 | €771.85 Million ≈ $902.38 Million |
€497.00K ≈ $581.05K |
0.001x | -99.78% |
| 2023-12-31 | €743.39 Million ≈ $869.10 Million |
€219.26 Million ≈ $256.34 Million |
0.295x | +169.93% |
| 2022-12-31 | €636.87 Million ≈ $744.57 Million |
€-268.60 Million ≈ $-314.02 Million |
-0.422x | -114.67% |
| 2021-12-31 | €1.04 Billion ≈ $1.22 Billion |
€-204.22 Million ≈ $-238.76 Million |
-0.196x | -64.27% |
| 2020-12-31 | €518.95 Million ≈ $606.71 Million |
€-62.07 Million ≈ $-72.56 Million |
-0.120x | +53.75% |
| 2019-12-31 | €312.90 Million ≈ $365.82 Million |
€-80.91 Million ≈ $-94.59 Million |
-0.259x | -224.54% |
| 2018-12-31 | €412.25 Million ≈ $481.97 Million |
€-32.85 Million ≈ $-38.40 Million |
-0.080x | -332.07% |
| 2017-12-31 | €484.97 Million ≈ $566.98 Million |
€-8.94 Million ≈ $-10.46 Million |
-0.018x | +60.68% |
| 2016-12-31 | €204.06 Million ≈ $238.57 Million |
€-9.57 Million ≈ $-11.19 Million |
-0.047x | -- |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more